Breaking Ground in Alzheimer’s Diagnosis: Simoa® p-Tau 217 Blood Test Receives FDA Breakthrough Device Designation
…Accessed March 26, 2024. https://www.quanterix.com/press-releases/quanterix-granted-breakthrough-device-designation-from-u-s-fda-for-blood-based-p-tau-217-test–for-alzheimers-disease/ Revised Criteria for Diagnosis and Staging of Alzheimer’s. AAIC. Accessed March 26, 2024. https://aaic.alz.org/diagnostic-criteria.asp Quanterix granted breakthrough device designation from U.S. FDA for blood-based pTau-181…
read more